GV has participated in a series D round for Fractyl Laboratories, which is developing minimally-invasive treatment for metabolic diseases.
Fractyl Laboratories, a US-based developer of a treatment for type 2 diabetes, closed a $44m series D round yesterday that included GV, the early-stage corporate venturing division of diversified conglomerate Alphabet.
The round, led by an unnamed, new investor, also featured True Ventures, General Catalyst, Bessemer Venture Partners, Domain Associates, Mithril Capital Management, Emergent Medical Partners, Deerfield Management Company and the IDO Fund.
Founded in 2010, Fractyl Laboratories is working on a minimally invasive treatment to reverse metabolic diseases. The…
